中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

158 records (took 0.021 seconds)

    DEVICE FOR PLACEMENT IN THE TRICUSPID ANNULUS
    31.
    发明申请
    DEVICE FOR PLACEMENT IN THE TRICUSPID ANNULUS 有权
    TRICUSPID ANNULUS中的放置装置

    公开(公告)号：US20140350662A1

    公开(公告)日：2014-11-27

    申请号：US14359646

    申请日：2012-11-21

    Applicant: Mor Research Applications Ltd.

    Inventor： Mordehay Vaturi

    IPC: A61F2/24

    CPC classification number: A61F2/24 ,  A61F2/2409 ,  A61F2/2412 ,  A61F2/2454 ,  A61F2/246 ,  A61F2/2463

    Abstract: A device (200) for implantation in or near an annulus of a tricuspid valve comprising at least one blood flow control element (202) adapted to capture a volume of blood therein. Optionally or alternatively, the blood flow control element is adapted to allow at least some volume of blood (406) to regurgitate through the annulus during at least some part of systole. Optionally or alternatively, the device comprises a relatively rigid annulus with an arc length of less than 300 degrees. Optionally or alternatively, the relatively rigid annulus comprises a plurality of tissue fixation elements positioned along no more than 300 degrees of a circumference of the annulus, for example to avoid damaging conduction pathways between an atria and a chamber.

    Abstract translation: 一种用于植入三尖瓣环或其附近的装置（200），包括适于捕获一定体积的血液的至少一个血流控制元件（202）。 任选地或替代地，血流控制元件适于允许至少一定体积的血液（406）在至少一部分收缩期间通过环带回流。 可选地或替代地，该装置包括弧形长度小于300度的相对刚性的环形空间。 可选地或替代地，相对刚性的环形空间包括多个组织固定元件，所述多个组织固定元件沿环形圆周不超过300度定位，例如以避免损坏心房和腔室之间的传导路径。

    Non-invasive prenatal genetic diagnosis using transcervical cells
    33.
    发明申请
    Non-invasive prenatal genetic diagnosis using transcervical cells 审中-公开
    非侵入性产前遗传诊断使用宫颈癌细胞

    公开(公告)号：US20040197832A1

    公开(公告)日：2004-10-07

    申请号：US10405698

    申请日：2003-04-03

    Applicant: Mor Research Applications Ltd.

    Inventor： Aliza Amiel ,  Moshe D. Fejgin

    IPC: G01N033/53 ,  G01N033/567

    CPC classification number: C12Q1/6879 ,  C12Q1/6841 ,  C12Q1/6883 ,  C12Q2600/156 ,  G01N33/689 ,  G01N2800/36 ,  G01N2800/368 ,  G01N2800/387

    Abstract: A method is provided for determining the gender and/or chromosomal abnormality, e.g. chromosomal aneuploidy of a fetus comprising identifying fetal cells in a transcervical cell sample obtained from a pregnant woman, for example with an antibody specific to the HLA-G antigen expressed only by extravillous trophoblast cells, and then subjecting the identified fetal cells to fluorescence in situ hybridization (FISH) with one or more probes for detecting the sex of the fetus or a chromosomal abnormality such as a monosomy, a trisomy or a polyploidy, e.g. triploidy.

    Abstract translation: 提供了一种用于确定性别和/或染色体异常的方法，例如， 胎儿的染色体非整倍性包括鉴定从孕妇获得的子宫颈细胞样品中的胎儿细胞，例如用仅由绒毛滋养层细胞表达的HLA-G抗原特异的抗体，然后使鉴定的胎儿细胞在原位荧光 杂交（FISH）与一个或多个用于检测胎儿性别的探针或染色体异常如单体，三体或多倍体，例如 三倍体

    METHODS FOR TREATING DIEASES ASSOCIATED WITH IMPAIRED MEVALONATE PRODUCTION
    34.
    发明公开
    METHODS FOR TREATING DIEASES ASSOCIATED WITH IMPAIRED MEVALONATE PRODUCTION 审中-公开

    公开(公告)号：US20240342134A1

    公开(公告)日：2024-10-17

    申请号：US18682201

    申请日：2022-08-09

    Applicant: Mor Research Applications Ltd.

    Inventor： Ohad S. Birk ,  Yuval Yogev

    IPC: A61K31/366 ,  A61K9/00 ,  A61P21/00

    CPC classification number: A61K31/366 ,  A61K9/0053 ,  A61P21/00

    Abstract: The use of mevalonolactone is provided for treating, preventing or alleviating diseases, disorders or conditions associated, directly or indirectly, with reduced mevalonic acid production in the mevalonate pathway, for example, due to damaged or hindered HMG CoA-reductase enzyme. Oral administration of mevalonolactone is provided for treating muscle cell and/or tissue damage caused at least in part due to impaired mevalonic acid production, as effected in diseases and disorders such as myopathy, statin-associated muscle symptom (SAMS), immune-mediated necrotizing myopathy (IMNM), rhabdomyolysis, muscular toxicity syndrome, myalgia, sarcopenia, and limb girdle muscular dystrophy (LGMD).

    EEG microstates analysis
    35.
    发明授权
    EEG microstates analysis 有权

    公开(公告)号：US12042293B2

    公开(公告)日：2024-07-23

    申请号：US16650875

    申请日：2018-09-21

    Applicant: Mor Research Applications Ltd. ,  Ramot at Tel-Aviv University Ltd.

    Inventor： Amir Glik ,  Miriam Furst-Yust ,  Felix Benninger

    IPC: A61B5/369 ,  A61B5/00 ,  A61B5/16

    CPC classification number: A61B5/369 ,  A61B5/165 ,  A61B5/4088 ,  A61B5/4842 ,  A61B5/7275

    Abstract: Using microstate data to evaluate Alzheimer's disease including dementia and/or mild cognitive impairment and/or depression and optionally provide treatment based on the diagnosis and/or modify treatment and/or diagnosis based on response to treatment, optionally as measured using microstate data. In one example, the method includes analyzing EEG data to generate one or more EEG parameter; and generating a risk for one or both of depression and MCI (mild cognitive impairment) based on said one or more EEG parameters. Optionally, the disease comprises MCI. Optionally, the disease comprises depression. Optionally, the one or more EEG parameter comprises a microstate-derived parameter. Optionally, the one or more EEG parameter comprises a microstate duration derived parameter.

    MITOCHONDRIAL TRANSPLANTATION AND USE THEREOF IN OCULAR DISEASES
    39.
    发明申请
    MITOCHONDRIAL TRANSPLANTATION AND USE THEREOF IN OCULAR DISEASES 有权

    公开(公告)号：US20220168358A1

    公开(公告)日：2022-06-02

    申请号：US17594141

    申请日：2020-04-03

    Applicant: Mor Research Applications Ltd.

    Inventor： Ziv Rotfogel ,  Keren Ben-Yaakov ,  Michal Simon

    IPC: A61K35/407 ,  A61P27/02

    Abstract: Methods for treatment of ocular diseases and conditions associated with mitochondrial dysfunction, mitochondrial destruction and/or mitochondrial depletion in the eye, are disclosed. These methods comprise the transplantation of viable exogenous, isolated mitochondria to ocular tissues. Mitochondrial transplantation is effective in treatment of, e.g., an ocular manifestation of a disease or disorder in a subject, an ophthalmic disease, disorder or condition associated with mitochondrial dysfunction, and/or an ocular ischemic insult in a subject.

Patent Agency Ranking